Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$12.00 USD
+11.85 (8,164.46%)
Updated Apr 23, 2024 03:59 PM ET
After-Market: $12.01 +0.01 (0.08%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Pieris Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 26 | 59 | 118 | 70 | 104 |
Receivables | 6 | 6 | 3 | 2 | 7 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 8 | 7 | 4 | 4 |
Total Current Assets | 39 | 73 | 128 | 76 | 115 |
Net Property & Equipment | 0 | 17 | 19 | 22 | 20 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 3 | 3 | 3 |
Total Assets | 39 | 95 | 154 | 105 | 141 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 9 | 2 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 12 | 17 | 8 | 10 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 21 | 25 | 13 | 11 |
Total Current Liabilities | 12 | 37 | 51 | 22 | 27 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 19 | 38 | 36 | 47 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 12 | 68 | 103 | 74 | 90 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 342 | 319 | 307 | 243 | 227 |
Retained Earnings | -315 | -290 | -257 | -211 | -174 |
Other Equity | 0 | 0 | 1 | 0 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 27 | 28 | 51 | 31 | 51 |
Total Liabilities & Shareholder's Equity | 39 | 95 | 154 | 105 | 141 |
Total Common Equity | 27 | 28 | 51 | 31 | 51 |
Shares Outstanding | 98.80 | 74.40 | 72.00 | 55.90 | 54.90 |
Book Value Per Share | 0.27 | 0.38 | 0.71 | 0.56 | 0.94 |
Fiscal Year End for Pieris Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 26 | 45 | 55 | 48 |
Receivables | NA | 6 | 1 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 6 | 11 | 11 | 11 |
Total Current Assets | NA | 39 | 59 | 66 | 61 |
Net Property & Equipment | NA | 0 | 0 | 16 | 17 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 1 | 1 |
Total Assets | NA | 39 | 59 | 88 | 82 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 3 | 8 | 6 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 9 | 13 | 9 | 10 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 1 | 18 | 27 |
Total Current Liabilities | NA | 12 | 29 | 34 | 43 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 1 | 12 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 12 | 29 | 47 | 67 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 342 | 341 | 340 | 319 |
Retained Earnings | NA | -315 | -310 | -300 | -304 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 27 | 31 | 41 | 15 |
Total Liabilities & Shareholder's Equity | NA | 39 | 59 | 88 | 82 |
Total Common Equity | 0 | 27 | 31 | 41 | 15 |
Shares Outstanding | 98.90 | 98.80 | 98.80 | 82.00 | 74.50 |
Book Value Per Share | 0.00 | 0.27 | 0.31 | 0.49 | 0.21 |